BioMimetic also reported year-end revenue of $1.5 million, down from last year’s $1.6 million revenue. According to BioMimetic President and CEO Samuel Lynch, much of 2010 was devoted to pushing the company’s lead product candidate, Augment Bone Graft, through the Food and Drug Administration’s approval process. Other lead products underwent clinical trials and development as well, according to the company news release.
Read the company news release about BioMimetic Therapeutics’ 4Q financial results.
Read other coverage about BioMimetic Therapeutics:
– FDA to Review Premarket Approval Application for BioMimetic Therapeutics’ Augment Bone Graft
– Millennium Research Group: Bone Graft Substitute Market to Reach $2.3B by 2015
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
